✦ LIBER ✦

Movement parameters that distinguish between voluntary movements and levodopa-induced dyskinesia in Parkinson’s disease

✍ Scribed by Noël L.W Keijsers; Martin W.I.M Horstink; Stan C.A.M Gielen

Book ID: 114156204
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 601 KB
Volume: 22
Category: Article
ISSN: 0167-9457
DOI: 10.1016/s0167-9457(02)00179-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Movement patterns of peak-dose levodopa-

Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease

✍ Jackie Gour; Roderick Edwards; Sarah Lemieux; Mehrdad Ghassemi; Mandar Jog; Chri 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 876 KB

Quantification of motor slowness in Park

Quantification of motor slowness in Parkinson's disease: Correlations between the tapping test and single joint ballistic movement parameters

✍ Thomas Boraud; François Tison; Christian Gross 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 454 KB

A hypothesis on the pathophysiological m

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment

✍ Dr. A. R. Crossman 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 843 KB

## Abstract Long‐term treatment of human Parkinson's disease with levodopa or dopamine agonists is often complicated by the appearance of abnormal involuntary movements (dyskinesias) that are extremely difficult to control. Little is known of the cause, pathophysiological mechanisms, or possible st

Fipamezole (JP-1730) is a potent α2 adre

Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

✍ Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurs 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Previous studies in the MPTP-lesioned primate model of Parkinson's disease have demonstrated that alpha(2) adrenergic receptor antagonists such as idazoxan, rauwolscine, and yohimbine can alleviate L-dopa-induced dyskinesia and, in the case of idazoxan, enhance the duration of anti-parkinsonian acti